Kermarec J, Sauvaget J
Nouv Presse Med. 1981 Feb 26;10(8):650-3.
Thirty-nine patients, 17 to 80 years old, were admitted to a pneumology department. The diagnosis was acute serious or severe respiratory tract infection in 25 patients, exacerbation of chronic bronchopulmonary infection in 6, purulent pneumonia in 4, purulent bronchitis in 4. 28 infecting organisms were identified: Gram-positive cocci (Pneumococcus: 6, Streptococcus: 8. Staphylococcus: 1) and 6 Haemophilus influenzae (3 of which were associated with 1 Pneumococcus) 7 Enterobacteria (isolated or associated). Local, biological and systemic tolerance was generally very good in the majority of patients. Cefotaxime at a daily dose of 2 g intramuscularly for 12 days, showed very good efficacy in the treatment of various bacterial infections of the lower respiratory tract. The activity was evident against a variety of organisms in respiratory infections. The in vitro results of the antibiogram which indicated a superiority of cefotaxime in some cases on other antibiotics currently used in these indications were confirmed by the clinical results.
39名年龄在17至80岁之间的患者入住了呼吸科。诊断结果为：25例急性重症或严重呼吸道感染，6例慢性支气管肺部感染加重，4例化脓性肺炎，4例化脓性支气管炎。共鉴定出28种感染病原体：革兰氏阳性球菌（肺炎球菌：6例，链球菌：8例，葡萄球菌：1例）以及6例流感嗜血杆菌（其中3例与1例肺炎球菌相关），7例肠杆菌（单独分离出或与其他病原体相关）。大多数患者的局部、生物学和全身耐受性总体上非常良好。每日剂量为2克的头孢噻肟肌肉注射12天，在治疗各种下呼吸道细菌感染方面显示出非常好的疗效。其活性在呼吸道感染中的多种病原体上均很明显。抗菌谱的体外结果表明，在某些情况下头孢噻肟比目前用于这些适应症的其他抗生素更具优势，这一点得到了临床结果的证实。
